Skip to Content
Merck
  • Surgical management of placenta accreta: to leave or remove the placenta?

Surgical management of placenta accreta: to leave or remove the placenta?

BJOG : an international journal of obstetrics and gynaecology (2014-01-01)
A Perez-Delboy, J D Wright
ABSTRACT

Abnromalities of placentation, including placenta accreta, represent a major source of morbidity and mortality among women. Traditional management consists of peripartum hysterectomy at the time of delivery, although more conservative treatments have also been developed recently. In this review we describe the available literature describing the operative approach and considerations for management of women with placenta accreta.

MATERIALS
Product Number
Brand
Product Description

Supelco
Methotrexate solution, 1.0 mg/mL in methanol with 0.1N NaOH, ampule of 1 mL, certified reference material, Cerilliant®
Methotrexate, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Methotrexate hydrate, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
Methotrexate hydrate, powder, BioReagent, suitable for cell culture, ≥98% (HPLC)
Sigma-Aldrich
Methotrexate hydrate, ≥98% (HPLC), powder
Sigma-Aldrich
Methotrexate, meets USP testing specifications
Methotrexate for peak identification, European Pharmacopoeia (EP) Reference Standard